RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Osteogenesis Imperfecta: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Narrative empowerment: life stories of young people with osteogenesis imperfecta and the reconstruction of public perceptions
Yiping Yu, Advances in Social Behavior Research (16 October 2026)
https://doi.org/10.54254/2753-7102/2026.37821
- 2.
Response to the Letter to the Editor on "Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity".
von Brackel Felix N et al., Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42873240/
- 3.
Patient-specific zebrafish models reveal a complex phenotypic spectrum in NBAS-associated atypical osteogenesis imperfecta.
Baird Daniel A et al., Bone (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42869115/
- 4.
Sugestão para Investigação — Três Hipóteses Terapêuticas para a Osteogênese Imperfeita - Research Proposal — Three Therapeutic Hypotheses for Osteogenesis Imperfecta
Deni da Silva Saez, Zenodo (CERN European Organization for Nuclear Research) (12 October 2026)
https://doi.org/10.5281/zenodo.23325484
- 5.
Fracture characteristics and outcomes in osteogenesis imperfecta: A systematic review
Lothar Seefried et al., Bone Reports (10 October 2026)
https://doi.org/10.1016/j.bonr.2026.101958
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588 · Recruiting · Phase 2 · Angitia Incorporated Limited
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07062588
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Osteogenesis Imperfecta
Osteogenesis imperfecta (brittle bone disease) is a group of genetic conditions causing fragile bones that fracture easily. Most cases are caused by mutations in collagen genes. Severity ranges from mild to severe. Bisphosphonate therapy strengthens bones, and new treatments including gene-based approaches are in trials.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
People with rare diseases are often represented through medical labels and vulnerability narratives. Osteogenesis imperfecta (OI), called "porcelain doll disease," is easily reduced to fragility, dependence, and incapacity. Charity-centered communication may attract attention but obscure aspirations, preferences, creativity. This case study explores how life narrative and artistic self-expression can reconstruct public perceptions of young people with OI. It focuses on "Mannie Group," a five-member female research and creative group formed on July 30, 2026, around Wang Mannie, a young woman with OI. Data include a semi-structured interview, field observation, informal conversations, and a participatory fashion show held on August 4, 2026, in Guangzhou, with about 100 audience members. Analysis covers Mannie's life narrative, experiences, self-expression, clothing preferences, mobility, and symbolic elements including clothing style, purple color, wing imagery, music, and the slogan "肆意的曼妮是曼妮."("Mannie in her fullest expression is simply Mannie") Findings show a gap between attention and understanding. Mannie's story challenges reductionist representation. The fashion show turned the body from a medical object into a medium of self-expression, with aesthetic choices based on Mannie's own ideas. Narrative empowerment can replace pity- and charity-centered images with recognition, equality, and appreciation, but artistic expression alone cannot remove structural barriers. It must be part of broader social and institutional empowerment.
Common Questions
What is Osteogenesis Imperfecta?
Osteogenesis imperfecta (brittle bone disease) is a group of genetic conditions causing fragile bones that fracture easily. Most cases are caused by mutations in collagen genes. Severity ranges from mild to severe. Bisphosphonate therapy strengthens bones, and new treatments including gene-based approaches are in trials.
How many clinical trials are available for Osteogenesis Imperfecta?
RareWays currently indexes 59 clinical trials for Osteogenesis Imperfecta, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Osteogenesis Imperfecta come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Osteogenesis Imperfecta.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.